{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:50:03Z","timestamp":1783403403202,"version":"3.54.6"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of Nirmatrelvir\/Ritonavir in the treatment of the Omicron variant of coronavirus disease 2019 (COVID-19).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 58 patients who were infected with the Omicron variant of COVID-19 were retrospectively collected. The patients were divided into two groups according to the treatment regimen they received. Patients in both groups were given Lianhua Qingwen capsules orally, three times\/day, 6\u2009g\/time. The study group was given Nirmatrelvir 300\u2009mg\/Ritonavir 100\u2009mg orally, q12h, for 5\u2009days, and the control group was not given any antiviral drugs. The two groups were compared in terms of the change in computed tomography (CT) values of COVID-19 nucleic acid, the negative conversion time of COVID-19 RNA, hospitalization time, adverse drug reactions and COVID-19 nucleic acid re-positive tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The time to increase the CT values in the study group was faster than that in the control group, and the CT values in the study group were significantly larger than in the control group on days four and seven (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05); The negative conversion time in the study group was shorter than the control group (Z\u2009=\u2009\u20132.424, <jats:italic>p\u2009=<\/jats:italic> 0.015), and the hospitalization time was also shorter (Z\u2009=\u2009\u20132.603, <jats:italic>p<\/jats:italic> =\u20090.009). There were no statistically significant adverse drug reactions during hospitalization in both groups (\u03c7<jats:sup>2<\/jats:sup> = 2.747, <jats:italic>p<\/jats:italic>\u2009=\u20090.097). None of the study group tested re-positive for SARS-CoV-2 nucleic acid after discharge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy of Nirmatrelvir\/Ritonavir in the treatment of the Omicron variant of COVID-19 was positive and had good tolerance in patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1161193","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:31:26Z","timestamp":1689262286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of Nirmatrelvir\/Ritonavir for treating the Omicron variant of COVID-19"],"prefix":"10.3389","volume":"10","author":[{"given":"Chaochao","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"ref1","year":"2022"},{"key":"ref2","year":"2021"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/d41586-021-03672-3","article-title":"Omicron likely to weaken COVID vaccine protection","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection[J]","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the Management of Drug-Drug Interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"ref7","year":"2022"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3760\/j.issn.1673-4777.2022.04.001","article-title":"New coronavirus pneumonia diagnosis and treatment plan (trial version 9) notice on the issuance of new coronavirus pneumonia diagnosis and treatment plan (trial version 9)","volume":"4","year":"2022","journal-title":"J Tradit Chin Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","article-title":"Heavily mutated omicron variant puts scientists on alert","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.12114\/j.issn.1007-9572.2021.00.348","article-title":"Epidemiological characteristics and prevention and control of omicron variant of novel coronavirus","volume":"1","author":"Minamata","year":"2022","journal-title":"Chin Gen Pract"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"Ren","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.11669\/cpj.2022.10.012","article-title":"The mechanism of action and clinical research of the new coronavirus treatment drug nematvir tablets\/ritonavir tablets","volume":"10","author":"Zhang Jingwen","year":"2022","journal-title":"Chin Pharm J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref15","year":"2022"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and Nirmatrelvir-ritonavir: Oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref17","year":"2022"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.3906\/sag-2106-250","article-title":"An update of antiviral treatment of COVID-19","volume":"51","author":"Yavuz","year":"2021","journal-title":"Turk J Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"22278450","DOI":"10.1101\/2022.08.04.22278450","article-title":"COVID-19 rebound after Paxlovid treatment during omicron BA.5 vs BA.2.12.1 subvariant predominance period","volume":"8","author":"Lindsey","year":"2022","journal-title":"medRxiv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3969\/j.issn.1672-8157.2022.05.014","article-title":"Medication analysis and rationality evaluation of patients with novel coronavirus pneumonia using combination packaging of nemavir tablets\/ritonavir tablets","volume":"19","author":"Liu Xiaolin","year":"2022","journal-title":"Chin J Drug Appl Monitor"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1161193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:31:32Z","timestamp":1689262292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1161193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":20,"alternative-id":["10.3389\/fmed.2023.1161193"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1161193","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"article-number":"1161193"}}